36 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
Act, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase 1 … approval under the FDA expanded access program. While there is no obligation to make product candidates
S-11
available to eligible patients as a result
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
.
In addition, the U.S. federal Right to Try Act, among other things, provides a federal framework for patients to access certain investigational new … enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. While there is no obligation to make product candidates
8-K
EX-10.1
yswuhmqofz
26 Dec 23
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
8:09am
DEFA14A
i1jwfcsi
26 Oct 23
Additional proxy soliciting materials
4:19pm
8-K
EX-10.1
ey2e78ih
18 May 23
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
8:40am
8-K
EX-10.1
pe52j10by9y
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
bccg0r9czx33e
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
gtpalco
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
kxqvedto l40me
10 Apr 23
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
4:46pm
8-K
EX-99.1
keapjbmgt5u5twf2ckq
19 Dec 22
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
7:15am